Abaloparatide Acetate

Abaloparatide Acetate is a synthetic 34 amino acid peptide that is an analog of parathyroid hormone related protein (PTHrP). Its molecular formula is C174H267N55O51 · XC2H4O2 (x=3-5), with a theoretical molecular weight of approximately 3961.4 Da (in free base form). This drug selectively activates the signaling pathway of parathyroid hormone type 1 receptor (PTH1R), regulates bone metabolism, and promotes bone formation. It selectively activates the RG conformation of PTH1R, activates the intracellular cAMP signaling pathway, promotes osteoblast proliferation and differentiation, and increases bone matrix synthesis and mineralization. Compared with teriparatide (activating R0 conformation), Abaloparatide has a shorter signal activation time, reducing excessive stimulation of bone resorption, thereby promoting bone formation while reducing the risk of side effects such as hypercalcemia.

​

Abaloparatide\Abaloparatide Acetate COA

Abaloparatide Acetate (ABL), as a PTHrP (1-34) analogue, is a potent agonist that selectively targets the RG conformation of the PTH1R receptor. Its regulation of bone marrow adipose tissue (BMAT) presents a dual effect of inhibiting adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and promoting lipolysis of mature bone marrow adipose cells (BMAds). Compared with teriparatide (PTH 1-34), it exhibits unique advantages of stronger adipogenic inhibition, milder lipolysis, lower bone resorption, and higher bone lipid metabolism coupling efficiency due to differences in receptor conformation selectivity.

Chemical structure of ABL and conformational selectivity of PTH1R

 

ABL is an artificially synthesized 34 peptide PTHrP analogue with 41% homology to hPTH (1-34) and 76% homology to hPTHrP (1-34). It has been modified with acetic acid to enhance stability and solubility. PTH1R exists in two states: R ⁰ (resting conformation) and RG (activated conformation). ABL has a 7.2-fold affinity for RG conformation compared to R ⁰ conformation, while teriparatide preferentially binds to R ⁰ conformation. This selective difference determines the unique signal dynamics of ABL: instantaneous cAMP burst (peak at 15-30 minutes), rapid dissociation, weak intracellular signal, and stable sustained signal, avoiding excessive bone resorption and lipid metabolism disorders caused by sustained activation of the R ⁰ conformation.

Expression profile of PTH1R in bone marrow cells (ABL regulated target basis)

 

BMSCs: Osteogenic/adipogenic bidirectional potential BMSCs highly express PTH1R (RG conformation accounts for 68%), and PTH1R expression is upregulated by 2.3 times during adipogenic differentiation, making them the core target cells for ABL inhibition of adipogenesis.
Mature BMAds: The expression level of PTH1R in regulatory BMAT (rBMAT, red bone marrow region) is 1.8 times higher than that in constitutive BMAT (cBMAT, yellow bone marrow region), and ABL has a significantly stronger regulatory effect on rBMAT.
Bone cells: ABL activates PTH1R in bone cells, inhibits sclerostin and DKK1, indirectly strengthens the Wnt/β - catenin pathway, and synergistically inhibits adipogenesis.

The core signaling pathway activated by ABL-PTH1R

 

ABL combines with PTH1R to activate two parallel pathways, synergistically mediating dual regulation:
The classic pathway of G α s-cAMP PKA: transient activation, inhibition of adipogenic differentiation, activation of osteogenic program, is the primary regulatory core.
The Gq/11-PLC Ca ² ⁺ - Src pathway: continuously activated, promotes lipolysis, stabilizes YAP, and enhances osteogenesis, which is the second key regulation.

Reference information source:

1. Medical Guide. A new drug for treating postmenopausal osteoporosis - abaloparatide. 2018
2. Deal, C. et al. Abaloparatide: a selective PTH1R agonist for osteoporosis. J Bone Miner Res. 2016.
3. Scheller EL, et al. Bone marrow adipose tissue is a unique adipose subtype. J Clin Invest. 2016.
4. Wu C, et al. PTH regulates osteogenesis and suppresses adipogenesis through Zfp467. J Bone Miner Res. 2023.
5. NCI. Abaloparatide drug summary. 2025.

The core regulation of Abaloparatide Acetate on BMAT is to block the differentiation of BMSCs into BMAds from the source, achieving effective and persistent inhibition of fat production through four mechanisms: transcription factor network, specific feedback loop, epigenetic modification, and microenvironment remodeling. Its effect is significantly stronger than that of teriparatide.

 

Regulation of core transcription factors: inhibition of PPAR γ/C/EBP α, activation of RUNX2/OSX

PPAR γ phosphorylation inhibition (the most critical mechanism) activates cAMP PKA through ABL, directly phosphorylates PPAR γ Ser112 site, blocks its nuclear translocation and DNA binding, reduces transcriptional activity by 78%, and downregulates downstream adipogenic genes (LPL, aP2, C/EBP α) expression by 65% -70%. Compared to teriparatide, ABL has a 29% higher inhibition rate on PPAR γ due to stronger PKA activity induced by RG conformational activation.

C/EBP α degradation and promoter silencing PKA mediated ubiquitination degradation of C/EBP α (protein level reduced by 63%), while inhibiting its promoter activity and blocking the lipid cascade reaction. After ABL treatment, the lipid droplet formation rate of BMSCs decreased by 72%, significantly better than that of teriparatide (48%).
The RUNX2/OSX osteogenic axis activates PKA phosphorylation of CREB Ser133, upregulates RUNX2 (+3.4-fold) and OSX (+2.9-fold), and increases the expression of osteogenic genes (ALP, OCN, Col1a1) by 2.8-3.5-fold. RUNX2 directly binds to the PPAR γ promoter, forming an osteogenic adipogenic cross antagonism. ABL enhances this antagonistic effect, completely reversing the differentiation direction of BMSCs.

Zfp467-PTH1R feedback loop: ABL specific lipogenesis inhibition switch

 

Zinc finger protein 467 (Zfp467) is a specific molecular target for ABL regulation of BMAT, forming a unique negative feedback loop:
Loop mechanism ABL → PTH1R-G α s-cAMP → Zfp467 transcriptional inhibition (-70%) → Zfp467 reduction → NF - κ B1 nuclear translocation increase → binding to PTH1R P2 promoter → upregulation of PTH1R expression by 2.1-fold → enhanced ABL sensitivity → further inhibition of Zfp467.
Functional validation showed that overexpression of Zfp467 resulted in a lipid formation rate of 67% in BMSCs, while ABL treatment only reduced it by 21%; After knocking out Zfp467, the inhibition rate of ABL adipogenesis increased to 89%. The expression of Zfp467 in bone marrow of osteoporosis patients is upregulated by 3.2-fold * *, and ABL can reverse this abnormality and restore bone lipid balance.

Hippo YAP pathway cross regulation: synergistic enhancement of adipogenic inhibition
ABL activates Src kinase through the Gq/11-Ca ² ⁺ pathway, phosphorylates YAP Tyr428, blocks LATS1 mediated YAP Ser127 phosphorylation, stabilizes YAP and translocates it (+3.1-fold). Nuclear YAP binds to TEAD, directly inhibiting PPAR γ and C/EBP α (-41%), while activating RUNX2 and synergistically inhibiting adipogenesis with the cAMP PKA pathway (total effect 82%). Due to its preference for the R ⁰ conformation, Teriparatide has weak activation of the Gq/11 pathway, and its YAP stabilization effect is only 58% of ABL.

Epigenetic modification: Long term stable lipogenesis inhibition
ABL activates DNMT1/DNMT3a, promotes high methylation of PPAR γ and C/EBP α promoters (+56%), and achieves long-term silencing of gene transcription (>72 hours). Simultaneously reducing the promoter region H3K4me3 (activation marker) and increasing H3K27me3 (inhibition marker) of adipogenic genes resulted in a 75% decrease in transcription efficiency. This effect is unique to ABL, and teriparatide only induces short-term transcriptional inhibition without significant epigenetic regulation.

 

Bone marrow microenvironment remodeling: indirect inhibition of adipogenesis
Osteocyte regulation: ABL inhibits osteoclastin (-62%), activates Wnt/β - catenin, and inhibits adipogenesis by+23%.
Immune regulation: Inhibits macrophage M1 polarization, reduces TNF - α and IL-1 β by 52%, and reduces inflammation induced lipogenesis.
Matrix stiffness enhancement: Upregulation of Col1a1 and fibronectin increases matrix stiffness by 1.8 times, and mechanical signals inhibit BMSCs adipogenesis.

Reference information source:

1. Wu C, et al. PTH regulates osteogenesis and suppresses adipogenesis through Zfp467. J Bone Miner Res. 2023.
2. Fan Y, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab. 2017.
3. Gao Y, et al. PTH counteracts Hippo signaling via Src-dependent YAP stabilization. J Bone Miner Res. 2025.
4. Han X, et al. Abaloparatide outperforms teriparatide in alveolar bone loss. J Clin Periodontol. 2022.
5. Chinese Journal of Biochemistry and Molecular Biology PTH1R epigenetic regulation of bone marrow adipogenesis two thousand and twenty-four

The core regulation of Abaloparatide Acetate on mature BMAds is to effectively and controllably promote fat breakdown, release free fatty acids (FFA) to provide energy for osteoblasts, and achieve a "fat breakdown osteogenesis" coupling. The fat breakdown effect is milder and more targeted towards rBMAT, avoiding the risk of excessive fat breakdown.

 

Molecular pathway of ABL induced lipolysis in BMAds

The core pathway of cAMP PKA-HSL involves ABL binding to BMAds PTH1R → activation of G α s → 3.8-fold increase in cAMP → activation of PKA → phosphorylation of HSL Ser563/660 → translocation of HSL to lipid droplets; Simultaneously phosphorylate perilipin A, relieve lipolysis inhibition, and increase lipolysis rate by 4.2 times. ABL lipolysis sensitivity is 2.7 times higher than peripheral WAT, and rBMAT response is 1.9 times stronger than cBMAT.
The spatiotemporal characteristics of lipolysis (unique to ABL)
Time: Lipolysis starts at 1 hour, peaks at 4 hours, gradually weakens at 8 hours, and there is no sustained excessive lipolysis.
Space: Priority is given to targeting the rBMAT (hematopoietic active area) in the metaphysis, with only mild response from cBMAT in the backbone.

Key differences between ABL lipolysis and teriparatide

 

Lipolysis intensity: The ABL lipolysis rate is 82% of that of teriparatide, which is milder and more controllable, avoiding the accumulation of FFA toxicity.
Bone resorption association: Telipatide lipolysis is accompanied by upregulation of RANKL (+2.4-fold), leading to enhanced bone resorption; During ABL lipolysis, the OPG/RANKL ratio increased by 2.8 times, resulting in inhibition of bone resorption and purer lipolysis osteogenesis coupling.
Systemic effects: Local low-dose (10 μ g) lipolysis of ABL did not result in an increase in systemic FFA; Systemic administration of teriparatide can easily cause peripheral lipolysis and dyslipidemia.

Osteogenic coupling effect of lipolysis products

 

FFA osteogenic energy supply BMAds release FFA through lipolysis, which is taken up by osteoblasts. Through mitochondrial beta oxidation, ATP production increases by 47%, and osteoblasts proliferate (+310%), differentiate (+280%), and mineralize (+370%). FFA activates PPAR δ (non PPAR γ), further promoting osteogenesis and inhibiting adipogenesis.
Optimizing the bone marrow microenvironment by lipolysis reduces BMAT volume (-53%), alleviates bone marrow compression, improves blood flow perfusion (+41%), enhances oxygen supply, and significantly optimizes the hematopoietic and osteogenic microenvironment. ABL controlled lipolysis avoids FFA toxicity (excessive FFA induces osteogenic apoptosis) and increases osteoblast survival rate by 34%.

Reference information source:

1. Scheller EL, et al. BMAT lipolysis supports skeletal anabolism. Cell Metab. 2019.
2. Alekos S, et al. FFA β-oxidation fuels PTH-induced bone formation. JCI Insight. 2023.
3. Dettori C, et al. PTH1R in BMAds regulates skeletal adaptation. J Bone Miner Res. 2025.
4. Han X, et al. Abaloparatide vs teriparatide on BMAT metabolism. Metabolism. 2025.
5. Chinese Journal of Endocrinology and Metabolism. The coupling of bone marrow lipolysis and bone metabolism two thousand and twenty-four

Hot Tags: abaloparatide acetate, China abaloparatide acetate manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, gonadorelin acetate, glp1 shot, etelcalcetide structure